EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions

Charalampos Skarlis iD, Efthalia Angelopoulou iD, Michail Rentzos, Sokratis G Papageorgiou iD, Maria Anagnostouli iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26199398 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Charalampos Skarlis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Immunogenetics Laboratory, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, NKUA, Aeginiti…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Neurodegenerative Diseases, Central Nervous System Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies (mAbs) have revolutionized the treatment landscape for neurological diseases, providing targeted, mechanism-based therapies for conditions ranging from autoimmune demyelinating disorders to neurodegenerative diseases. In multiple sclerosis (MS), mAbs against CD20, CD52, and α4-integrins offer disease-modifying efficacy by altering immune responses, depleting B cells, or blocking leukocyte migration into the central nervous system (CNS). Similarly, novel agents under investigation, such as frexalimab and foralumab, modulate T and B cell interactions and regulatory immunity. In neuromyelitis optica spectrum disorder (NMOSD), mAbs targeting IL-6, the complement cascade, and B cell lineage have demonstrated significant clinical benefit in preventing relapses and disability. In Alzheimer’s disease (AD), several anti-amyloid mAbs have gained regulatory approval. Anti-tau and anti-α-synuclein antibodies, though promising, have shown limited efficacy to date in AD and parkinson’s disease (PD), respectively. The evolving armamentarium of mAbs reflects a paradigm shift toward personalized neuroimmunology and neurodegeneration-targeted treatments, based on ongoing clarification of molecular and neuroinflammatory mechanisms. In this context, the present review summarizes current evidence on mAbs used in CNS disorders, with an emphasis on their pathophysiological targets, molecular mechanisms, clinical efficacy, and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalNeurodegenerative DiseasesCentral Nervous System DiseasesHumansAnimalsNeuromyelitis OpticaCentral Nervous SystemMultiple Sclerosis

Stichwörter der Autor:innen

Alzheimer’s disease (AD)Parkinson’s disease (PD)amyotrophic lateral sclerosiscentral nervous system (CNS)molecular mechanismsmonoclonal antibodies (mAbs)multiple sclerosis (MS)neuroinflammationneuromyelitis optica spectrum disorder (NMOSD)therapeutics

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Research Immunogenetics Laboratory, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, NKUA, Aeginition University Hospital, Vas. Sofias 72-74, 11528 Athens, Greece.
  • Multiple Sclerosis and Demyelinating Diseases Unit, Center of Expertise for Rare Demyelinating and Autoinflammatory Diseases of CNS, First Department of Neurology, School of Medicine, National and Kapodistrian Universit…
  • Neurodegenerative Diseases and Rare Dementias Unit, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, NKUA, Aeginition University Hospital, Vas. Sofias 72-74, 11528 Athen…
  • Neuromuscular Diseases Unit, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, NKUA, Aeginition University Hospital, Vas. Sofias 72-74, 11528 Athens, Greece.

ORCID-Profile: Charalampos Skarlis, Efthalia Angelopoulou, Sokratis G Papageorgiou, Maria Anagnostouli

Zitieren

APA

Skarlis, C., Angelopoulou, E., Rentzos, M., Papageorgiou, S. G., & Anagnostouli, M. (2025). Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199398

Vancouver

Skarlis C, Angelopoulou E, Rentzos M, Papageorgiou SG, Anagnostouli M. Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199398

BibTeX
@article{Skarlis2025,
  author = {Skarlis, Charalampos and Angelopoulou, Efthalia and Rentzos, Michail and Papageorgiou, Sokratis G and Anagnostouli, Maria},
  title = {Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26199398}
}
Kostenlos starten →